Merck Alzheimer's drug fails in 1 study; another continues
Tuesday, 14 February 2017 () *By The Canadian Press*
KENILWORTH, N.J. — Merck & Co. will stop its study of an experimental Alzheimer's drug in people with mild or moderate symptoms because interim results showed "virtually no chance" of any benefit.
However, the drugmaker said Tuesday it will continue another study of the drug, verubecestat, in patients who don't yet show symptoms. They have some memory problems, but can still perform daily activities.
The two studies were intended to enable Merck to seek regulators' approval... // Read Full Article
Researchers found that the new promising Alzheimer’s drug verubecestat did not work. Dr. Roger Perlmutter, president of Merck Research Laboratories, stated, “While we are disappointed that a benefit was not observed in this study, our work continues [to study the impact of] verubecestat in people...
KENILWORTH, N.J. (AP) — Merck & Co. will stop its study of an experimental Alzheimer’s drug in people with mild or moderate symptoms because interim results... Seattle Times - Front PageAlso reported by •Newsmax
(Reuters) - Merck & Co Inc said it would halt a late-stage trial of its drug in patients with mild to moderate Alzheimer's disease after an external panel... Reuters - HealthAlso reported by •Wall Street Journal •Business Wire